Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ligand Pharmaceuticals Inc (LGND): David M. Knott of Dorset Management Resigned from the Board

Page 1 of 5

David M. Knott‘s Dorset Managment, recently filed an amended 13D, with the US SEC, reporting David Knott’s resignation from the board of the directors of Ligand Pharmaceuticals Inc (NASDAQ:LGND), for reasons that are unconnected to the company. Dorset Management owns 1.30 million shares of Ligand Pharmaceuticals (NASDAQ:LGND), which amass 6.2% of the company’s outstanding stock. In its last 13F filing (for the end of March), Dorset Management reported a slightly lower stake of 1.28 million shares.

medication, pharmacist, shelf, care, pharmaceutical, medical, day, drug, clinic, medicament, drugstore, treatment, ill, smiling, medicine, pharmaceutics, of, hospital,

wavebreakmedia/Shutterstock.com

Follow Ligand Pharmaceuticals Inc (NASDAQ:LGND)
Trade (NASDAQ:LGND) Now!

Ligand Pharmaceuticals (NASDAQ:LGND) is a biopharmaceutical company that works on creating technologies that will enable other pharmaceutical companies to develop and produce new drugs. Earlier this month, Ligand Pharmaceuticals has acquired economic rights to a variety of programs owned by CorMatrix®. Over the past 12 months, the company’s shares have gained 36.56%. For the first quarter of 2016, Ligand Pharmaceuticals (NASDAQ:LGND) reported earnings per share of $0.97 and revenue of $29.65 million, beating the estimates of $0.67 and $26.45 million, respectively. A couple of weeks ago, Roth Capital reiterated its ‘buy’ rating on Ligand Pharmaceuticals’ stock, with a price target of $147.00.

According to our database, the number of hedge funds bullish on Ligand Pharmaceuticals (NASDAQ:LGND) increased by four recently, and at the end of March the company was in 20 hedge funds’ portfolios, with Dorset Management holding the biggest position, valued at $128.5 million. Coming in second was Amy Minella’s Cardinal Capital, which reported a position worth $89.9 million in stock. Remaining investors long the stock encompassed Peter Muller’s PDT Partners, Jim Simons’s Renaissance Technologies, and Ken Fisher’s Fisher Asset Management.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
David M. Knott 1,298,813 1,666 1,300,479 1,843 1,302,322 6.2%
Dorset Management Corporation 11 1,196,257 1,666 1,197,923 0 1,197,923 5.8%

David M. Knott
David M. Knott
Dorset Management

Page 1 of 5 – SEC Filing

 

 

UNITED STATES

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

 

 

 

SCHEDULE 13D

 

 

Under the Securities Exchange Act of 1934
(Amendment No. 7)*

 

Ligand Pharmaceuticals Incorporated

(Name of Issuer)

 

Common Stock, par value $0.001 per share

(Title of Class of Securities)

 

53220K504

(CUSIP Number)

 

David M. Knott

Dorsett Management Corporation

485 Underhill Boulevard, Suite 205

Syosset, New York 11791

(516) 364-0303

 

May 23, 2016

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1 (f) or 240.13d-1 (g), check the following box  x

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §13d-7 (b) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 


Follow Ligand Pharmaceuticals Inc (NASDAQ:LGND)
Trade (NASDAQ:LGND) Now!
Page 1 of 5

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!